Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

linigliptin

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

- PMLiVE

Another setback for Lilly as lymphoma drug fails

Late-stage candidate enzastaurin shows disappointing phase III results

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Lilly expects to submit five drugs for US approval in 2013

Hopes FDA submissions will help offset patent losses for Zyprexa and Cymbalta

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

- PMLiVE

Novo Nordisk launches new US insulin campaign

US IndyCar driver, diabetic and FlexPen user Charlie Kimball fronts activities

- PMLiVE

Infographic: Type 2 diabetes in Brazil

Key facts about the chronic condition's impact in the emerging market

- PMLiVE

Brazil: Patient access and education in type 2 diabetes

As the prevalence of diabetes increases in Brazil, the healthcare system needs to respond 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links